Tocilizumab Therapy for Adult-Onset Still's Disease

Patient Selection and Treatment Criteria

The American College of Rheumatology suggests that patients with Adult-Onset Still's Disease (AOSD) who have failed multiple biologics and targeted therapies may be candidates for tocilizumab therapy 6
Patients with AOSD who have demonstrated symptom recurrence with 4-week dosing intervals may require more frequent dosing, such as every 2 weeks, as supported by literature 9, 10
The European League Against Rheumatism recommends that patients with AOSD receive tocilizumab at a dose of 8 mg/kg every 4 weeks, with increases based on clinical response 1, 2, 3, 4, 5, 6, 7, 8

The optimal dosing frequency for tocilizumab in AOSD patients is every 2 weeks, as supported by clinical evidence 9, 10
Tocilizumab can be administered via home infusion, which reduces healthcare costs and improves quality of life while maintaining safety 4, 7

Patients receiving tocilizumab should be monitored regularly for signs of infection, as infectious complications are a primary concern with this therapy 9, 10
Regular laboratory monitoring, including complete metabolic panels, is necessary for patients receiving tocilizumab 9
Ophthalmology follow-up is recommended for patients with pre-existing cataracts and glaucoma 2

A multicenter retrospective study demonstrated that tocilizumab produced rapid and maintained improvement in refractory AOSD patients, with joint manifestations decreasing from 97.1% to 32.4% at 1 year, fever from 58.8% to 5.9%, and median prednisone dose reduced from 13.8 mg/day to 2.5 mg/day 1, 3, 8
Tocilizumab has been shown to be effective in reducing inflammatory markers and improving clinical complaints in AOSD patients, with some patients achieving remission and discontinuing treatment without relapse 6